Jasper Therapeutics (NASDAQ:JSPR) Stock Falls 7% – Here’s What Happened

Jasper Therapeutics, Inc. (NASDAQ:JSPR)’s share price traded down 7% on Tuesday. The company traded as low as $15.03 and last traded at $15.2310. 2,052 shares were traded during trading, a decline of 92% from the average daily volume of 26,654 shares. The stock had previously closed at $16.37.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. William Blair initiated coverage on Jasper Therapeutics in a report on Wednesday, October 14th. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, Piper Sandler initiated coverage on Jasper Therapeutics in a research report on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $220.00.

Jasper Therapeutics Stock Performance

The firm has a market capitalization of $16.35 million, a PE ratio of -0.31 and a beta of 3.30. The stock’s 50-day simple moving average is $17.08 and its 200-day simple moving average is $24.49.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Friday, August 14th. The company reported ($3.00) EPS for the quarter, topping the consensus estimate of ($8.03) by $5.03. As a group, analysts predict that Jasper Therapeutics, Inc. will post -28.98 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation. Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.